https://www.biospace.com/article/releases/acurx-pharmaceuticals-inc-reports-third-quarter-2023-results-and-provides-business-update/?s=80
https://ir.acurxpharma.com/news-events
https://finance.yahoo.com/quote/ACXP231215C00001000?p=ACXP231215C00001000
https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/tm2330757d1_ex99-1.htm
https://www.pharmaceutical-technology.com/data-insights/ibezapolstat-acurx-pharmaceuticals-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/
https://www.wtvy.com/prnewswire/2023/11/02/acurx-announces-positive-top-line-ibezapolstat-phase-2-efficacy-results-with-96-clinical-cure-rate-patients-with-c-difficile-infection/?outputType=amp
https://www.linkedin.com/posts/david-luci-acurx_acurxpharma-acxp-hcwainwright-activity-7046880312215166976-Xkds
https://www.pharmaceutical-technology.com/data-insights/ibezapolstat-acurx-pharmaceuticals-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval-2/
https://www.linkedin.com/posts/david-luci-acurx_nasdaq-acxp-antibiotics-activity-7123310303437623298-rq4_
https://www.acurxpharma.com/pipeline/publications
https://finance.yahoo.com/quote/ACXP231117C00001000?p=ACXP231117C00001000
